

PROVIDER BULLETIN

PROVIDER INFORMATION



January 9, 2018

New Drugs, Aimovig (erenumab), Fremanezumab and Galcanezumab Will Require PA

Aimovig (erenumab), fremanezumab and galcanezumab are new drug products anticipated to be approved for once-monthly injections for the prevention of migraine. Aimovig (erenumab) is expected to be approved on or before May 18, 2018. Fremanezumab and galcanezumab are expected to be approved in the latter part of 2018. Upon launch, Aimovig (erenumab), fremanezumab and galcanezumab will require prior authorization (PA) prior to use. The criteria for approval is based on FDA approved product labeling. Requests will be reviewed when patient-specific documentation has been provided. Please note, the brand name is not yet known for fremanezumab and galcanezumab.

The intent of this PA is to ensure appropriate selection of patients for treatment according to FDA approved product labeling. The Aimovig (erenumab), fremanezumab, and galcanezumab PA defines appropriate use as use in patients who have an FDA approved indication, who are receiving the FDA labeled dose, and who do not have any FDA labeled contraindications.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence based care for our members. One method for doing so is through the prior authorization process. The primary purpose is to ensure that evidence based care is provided to our subscribers, driving quality, safety and affordability.

Products Impacted

This PA program applies to commercial lines of business **and** the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare

The criteria for approval is based on FDA approved product labeling. Drug-specific PA criteria will be developed and posted once available. Medical policy can be accessed using the Blue Cross and Blue Shield of Minnesota provider link.

- Access **providers.bluecrossmn.com**
- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management

CoverMyMeds prior authorization request service

As a reminder, CoverMyMeds (CMM) is a free service to providers which allows quick and easy submission of PA requests. Experience with CMM by other plans has demonstrated marked reductions in physician office call-backs regarding PA requests, after CMM is implemented. PA requests may also continue to be faxed to their review destination external to the CMM portal, as is the current practice.

You may access CMM at www.covermymeds.com. Select Help (top right of the web page) to view FAQs and Support tutorials (3-5 minutes), including live online chat support to help you get started. You will need to open a CMM account to submit requests using the portal.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.